Bavarian Nordic Stock Falls on Plans to Raise $50M for Vaccine

Sheridan, Cormac
December 2009
BioWorld International;12/2/2009, Vol. 14 Issue 48, p1
This article reports on a decline in the value of stocks of Bavarian Nordic A/S in November 2009 as the company plans to raise funds to finance the development of its Imvamune next-generation smallpox vaccine. The Danish company's stocks fell more than three percent. The vaccine can be used by people with skin disorders and immune deficiencies. The company was able to secure contracts for Imvamune from the U.S. government.


Related Articles

  • Bavarian Gets $83M Rights Offering For Imvamune.  // Bioworld Week;4/2/2007, Vol. 15 Issue 14, p5 

    The article reports that Kvistgard, Denmark-based Bavarian Nordic AS has reported its gross proceeds of $83.3 million from a rights offering of $1.3 million or 465 million Danish krone (DKK) shares, to be used on its smallpox vaccine development and other pipeline programs. The shares, which had...

  • Bavarian Nordic Rises On First Vaccine Approval. Sheridan, Cormac // BioWorld International;8/14/2013, Vol. 18 Issue 33, p5 

    The article reports on the 6.6% increase in pharmaceutical company Bavarian Nordic A/S shares. It notes that this increase resulted from European Commission's approval of Bavarian Nordic's third-generation smallpox vaccine Imnavex which is based on a modified vaccinia Ankara (MVA) vector. The...

  • Bavarian Nordic Rises on First Vaccine Approval. Sheridan, Cormac // BioWorld Today;8/8/2013, Vol. 24 Issue 151, p1 

    The article reports on the increase in shares of Bavarian Nordic A/S following news that the European Commission had approved its third-generation smallpox vaccine Imvanex. The vaccine is based on a modified vaccinia Ankara (MVA) vector. On May 30, 2013, a positive opinion was issued by the...

  • Acambis and Bavarian Nordic Vie for Smallpox Vaccine Contract. Bush, Laura // Pharmaceutical Technology;Sep2005, Vol. 29 Issue 9, p24 

    Reports on the issuance of a request for proposals by the U.S. Department of Health and Human Services to acquire the doses of modified vaccinia Ankara (MVA) vaccine, a highly attenuated live smallpox vaccine. Competition between pharmaceutical firms Acambis PLC and Bavarian Nordic AS for the...

  • Bavarian Nordic Wins Janssen Contract.  // Contract Pharma;Oct2015, Vol. 17 Issue 8, p100 

    The article reports that biotechnology company Bavarian Nordic A/S was awarded a subcontract from Crucell Holland, a pharmaceutical subsidiaries of Johnson & Johnson, to support the advanced development and manufacturing of the Ebola prime-boost vaccine regimen.

  • OTHER NEWS TO NOTE.  // BioWorld International;11/26/2008, Vol. 13 Issue 48, p2 

    This section offers news briefs on the biotechnology industries. Asterand plc has completed a placement of 4.3 million shares at 15 pence each. Bavarian Nordic A/S received a $25 million milestone payment from the U.S. government by submitting safety data from a Phase II trial of smallpox...

  • GOVERNMENT OF CANADA PROCURES IMVAMUNE SMALLPOX VACCINE.  // Worldwide Biotech;Jan2009, Vol. 21 Issue 1, p6 

    The article reports on the contract awarded by Public Works and Government Services Canada to Bavarian Nordic in January 2009 for the delivery of Imvamune, a Modified Vaccinia Ankara (MVA)-based, third generation smallpox vaccine. As stated, the procurement will be used by the Canadian...

  • Production of smallpox vaccine approved.  // Pharmaceutical Technology Europe;Nov2006, Vol. 18 Issue 11, p14 

    The article reports on the approval of the production facility of Bavarian Nordic AS in Kvistgard, Denmark by the Danish Medicines Agency. After the authorization, the company could start to operate as a large-scale commercial production of smallpox vaccine. On the other hand, the company...

  • Bavarian's Smallpox Vaccine Pact Worth Up To $1.6 Billion. Sheridan, Cormac // BioWorld International;6/6/2007, Vol. 12 Issue 23, p1 

    The article reports on the contract won by Bavarian Nordic A/S to supply a stockpile of next-generation safe smallpox vaccines to the U.S. Department of Health and Human Services. The pharmaceutical company is expected to earn a total of $1.6 billion from the contract. The vaccine produced by...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics